QV Investors Inc. Makes New Investment in Stryker Corporation $SYK

QV Investors Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,320 shares of the medical technology company’s stock, valued at approximately $8,901,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Amundi raised its holdings in shares of Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after acquiring an additional 192,447 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Stryker by 8.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after acquiring an additional 65,333 shares in the last quarter. Veritas Asset Management LLP purchased a new stake in shares of Stryker in the 2nd quarter valued at approximately $168,057,000. Bank of America Corp DE acquired a new position in Stryker in the 2nd quarter worth approximately $1,404,284,000. Finally, Rakuten Investment Management Inc. acquired a new position in Stryker in the 2nd quarter worth approximately $18,646,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Analyst Ratings Changes

SYK has been the topic of several research analyst reports. Canaccord Genuity Group lowered their price objective on shares of Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. BMO Capital Markets restated an “outperform” rating and issued a $317.00 target price on shares of Stryker in a report on Wednesday, September 9th. Citigroup reduced their target price on Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, September 10th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Trading Up 2.2%

NYSE:SYK opened at $304.59 on Wednesday. The stock has a market cap of $116.83 billion, a PE ratio of 31.56, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $392.55. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s 50-day moving average is $297.53 and its two-hundred day moving average is $312.37.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.